Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Ceftibuten-Ledaborbactam Etzadroxil in Healthy Adults
NCT06733675Phase 1Recruiting
- Sponsor
- Basilea Pharmaceutica
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Reversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of ceftibuten and ledaborbactam etzadroxil in bacterial infection (5 arms), sponsored by Basilea Pharmaceutica. Primary endpoints: Area Under the Curve from Time Zero to Infinity, Maximum Plasma Concentration and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
ceftibutenledaborbactam etzadroxil
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT06733675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06733675.